EmesisGIP EMESISNCT07687589
The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals
A study testing Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide and Apomorphine Injectable Solution in people with Emesis, run by University of Copenhagen at 1 site in Denmark.
Trial summary
This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Emesis
- What is being tested?
- Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide and Apomorphine Injectable Solution
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- 1 siteDenmark
- Study dates
- 19 May 2026to 28 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men or women, age of 18-60 years
- BMI between 19-27 kg/m2 (both included)
- informed consent
Who cannot join
- Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months
- Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery)
- Neurological disorders affecting nausea (e.g. severe migraines and neuropathy)
- Any known eating disorders (e.g. anorexia nervosa and bulimia)
- Pregnancy or breastfeeding
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (> 2 times normal values) or present hepatobiliary disease
Show all 10Show fewer
- Kidney disease (estimated glomerular filtration rate (eGFR)<90 ml/min/1.73 m2) at screening
- Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV)
- Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes
- Any condition that the investigator evaluates would interfere with study participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site
Center for Clinical Metabolic Research, Herlev-Gentofte Hospital
Hellerup, 2900
About this study
This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.
- Conditions
- Emesis
- Being tested
- Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide, Apomorphine Injectable Solution, Saline (0.9% NaCl)
- Keywords
- GIP, emesis, GLP-1, incretin hormones, nausea
- Medical subject headings
- Vomiting, Nausea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Glucose-dependent Insulinotropic Polypeptide (GIP)Other
GIP - gut hormone
GLP-1 (7-36) amideOther
gut hormone - GLP-1(7-36)NH2
Apomorphine Injectable SolutionOther
used as a tool to induce nausea
Saline (0.9% NaCl)Other
Placebo
| Study group | Role | What they receive |
|---|---|---|
| s.c. injection of GLP-1 and infusion of saline | Active comparator | Not described Receives: Other: GLP-1 (7-36) amide; Other: Saline (0.9% NaCl) |
| s.c. injection of GLP-1 and infusion of GIP | Active comparator | Not described Receives: Other: Glucose-dependent Insulinotropic Polypeptide (GIP); Other: GLP-1 (7-36) amide |
| s.c. injection of apomorphine and infusion of saline | Active comparator | Not described Receives: Other: Apomorphine Injectable Solution; Other: Saline (0.9% NaCl) |
| s.c. injection of apormorphine and infusion of GIP | Active comparator | Not described Receives: Other: Glucose-dependent Insulinotropic Polypeptide (GIP); Other: Apomorphine Injectable Solution |
| s.c. injection of saline and infusion of GIP | Placebo comparator | Not described Receives: Other: Glucose-dependent Insulinotropic Polypeptide (GIP); Other: Saline (0.9% NaCl) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in GLP-1 induced nausea intensity
The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.
Measured: From enrollment to the end of treatment at up to 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2026
- Study start19 May 2026
- Primary completion30 Nov 2026 (estimated)
- Study completion28 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EmesisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Double-blinded, randomized, placebo-controlled, crossover study
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 14 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lærke Smidt Gasbjerg, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07687589
- Sponsor's protocol ID
- H-25050058
- Acronym
- GIP EMESIS
- Status last verified
- May 2026
- First submitted
- 25 Jun 2026
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals
- ClinicalTrials.gov ID
- NCT07687589
- Acronym / sponsor ID
- GIP EMESIS / H-25050058
- Conditions
- Emesis
- Keywords
- GIP, emesis, GLP-1, incretin hormones, nausea
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 14 participants (estimated)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Study start
- 19 May 2026 (actual)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 28 Apr 2027 (estimated)
- First posted
- 7 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
- Model description
- Double-blinded, randomized, placebo-controlled, crossover study
| Arm | Type | Receives |
|---|---|---|
| s.c. injection of GLP-1 and infusion of saline | Active comparator | Other: GLP-1 (7-36) amide, Other: Saline (0.9% NaCl) |
| s.c. injection of GLP-1 and infusion of GIP | Active comparator | Other: Glucose-dependent Insulinotropic Polypeptide (GIP), Other: GLP-1 (7-36) amide |
| s.c. injection of apomorphine and infusion of saline | Active comparator | Other: Apomorphine Injectable Solution, Other: Saline (0.9% NaCl) |
| s.c. injection of apormorphine and infusion of GIP | Active comparator | Other: Glucose-dependent Insulinotropic Polypeptide (GIP), Other: Apomorphine Injectable Solution |
| s.c. injection of saline and infusion of GIP | Placebo comparator | Other: Glucose-dependent Insulinotropic Polypeptide (GIP), Other: Saline (0.9% NaCl) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Men or women, age of 18-60 years
- BMI between 19-27 kg/m2 (both included)
- informed consent
Key exclusion criteria (10 listed)
- Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months
- Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery)
- Neurological disorders affecting nausea (e.g. severe migraines and neuropathy)
- Any known eating disorders (e.g. anorexia nervosa and bulimia)
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Glucose-dependent Insulinotropic Polypeptide (GIP)GIP - gut hormone | Other | s.c. injection of GLP-1 and infusion of GIP, s.c. injection of apormorphine and infusion of GIP, s.c. injection of saline and infusion of GIP |
| GLP-1 (7-36) amidegut hormone - GLP-1(7-36)NH2 | Other | s.c. injection of GLP-1 and infusion of GIP, s.c. injection of GLP-1 and infusion of saline |
| Apomorphine Injectable Solutionused as a tool to induce nausea | Other | s.c. injection of apomorphine and infusion of saline, s.c. injection of apormorphine and infusion of GIP |
| Saline (0.9% NaCl)Placebo | Other | s.c. injection of GLP-1 and infusion of saline, s.c. injection of apomorphine and infusion of saline, s.c. injection of saline and infusion of GIP |
Primary outcome
Change in GLP-1 induced nausea intensity
Time frame: From enrollment to the end of treatment at up to 12 weeks.
The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Emesis
Not yet recruiting
Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery
PONV
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis: A Randomized Controlled Trial
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruiting
Binaural Beats and Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy
Laparoscopic Cholecystectomy
RecruitingPhase 2
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
Breast Cancer
Not yet recruitingObservational study
Diagnostic and Psychometric Validation of the FRENCH HELP Scale in Hyperemesis Gravidarum
Hyperemesis Gravidarum, Nausea and Vomiting of Pregnancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide and Apomorphine Injectable Solution in people with Emesis, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in GLP-1 induced nausea intensity (time frame: From enrollment to the end of treatment at up to 12 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.